期刊
ONCOTARGET
卷 5, 期 18, 页码 8750-8764出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2373
关键词
Ovarian Cancer; Patient-derived xenograft; cancer stem cells; chemoresistance; animal models of cancer
资金
- UAB Medical Scientist Training Program [NIGMS T32GM008361]
- Norma Livingston Ovarian Cancer Foundation
- University of Alabama at Birmingham Center for Clinical and Translational Science [5UL1RR025777]
- Department of Defense Ovarian Cancer Research Academy [OC093443]
- CDMRP [546105, OC093443] Funding Source: Federal RePORTER
A cornerstone of preclinical cancer research has been the use of clonal cell lines. However, this resource has underperformed in its ability to effectively identify novel therapeutics and evaluate the heterogeneity in a patient's tumor. The patient-derived xenograft (PDX) model retains the heterogeneity of patient tumors, allowing a means to not only examine efficacy of a therapy, but also basic tenets of cancer biology in response to treatment. Herein we describe the development and characterization of an ovarian-PDX model in order to study the development of chemoresistance. We demonstrate that PDX tumors are not simply composed of tumor-initiating cells, but recapitulate the original tumor's heterogeneity, oncogene expression profiles, and clinical response to chemotherapy. Combined carboplatin/paclitaxel treatment of PDX tumors enriches the cancer stem cell populations, but persistent tumors are not entirely composed of these populations. RNA-Seq analysis of six pair of treated PDX tumors compared to untreated tumors demonstrates a consistently contrasting genetic profile after therapy, suggesting similar, but few, pathways are mediating chemoresistance. Pathways and genes identified by this methodology represent novel approaches to targeting the chemoresistant population in ovarian cancer
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据